News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
787,318 Results
Type
Article (58983)
Company Profile (450)
Press Release (727884)
Multimedia
Podcasts (137)
Webinars (18)
Section
Business (224517)
Career Advice (2717)
Deals (38194)
Drug Delivery (125)
Drug Development (87817)
Employer Resources (180)
FDA (17588)
Job Trends (16468)
News (378961)
Policy (36358)
Tag
Academia (2908)
Academic (2)
Accelerated approval (12)
Adcomms (27)
Allergies (106)
Alliances (55597)
ALS (123)
Alzheimer's disease (1585)
Antibody-drug conjugate (ADC) (185)
Approvals (17565)
Artificial intelligence (372)
Autoimmune disease (36)
Automation (20)
Bankruptcy (389)
Best Places to Work (12377)
BIOSECURE Act (21)
Biosimilars (139)
Biotechnology (305)
Bladder cancer (98)
Brain cancer (40)
Breast cancer (399)
Cancer (3150)
Cardiovascular disease (252)
Career advice (2286)
Career pathing (34)
CAR-T (207)
CDC (39)
Cell therapy (565)
Cervical cancer (25)
Clinical research (71953)
Collaboration (1147)
Company closure (3)
Compensation (732)
Complete response letters (34)
COVID-19 (2874)
CRISPR (70)
C-suite (382)
Cystic fibrosis (123)
Data (3237)
Decentralized trials (2)
Denatured (48)
Depression (80)
Diabetes (375)
Diagnostics (6855)
Digital health (25)
Diversity (10)
Diversity, equity & inclusion (46)
Drug discovery (170)
Drug pricing (152)
Drug shortages (32)
Duchenne muscular dystrophy (154)
Earnings (94132)
Editorial (50)
Employer branding (22)
Employer resources (157)
Events (126388)
Executive appointments (922)
FDA (19444)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1026)
Gene editing (151)
Generative AI (35)
Gene therapy (447)
GLP-1 (918)
Government (5018)
Grass and pollen (7)
Guidances (214)
Healthcare (20273)
HIV (44)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (186)
Immuno-oncology (11)
Indications (42)
Infectious disease (3071)
Inflammatory bowel disease (163)
Inflation Reduction Act (13)
Influenza (75)
Intellectual property (128)
Interviews (469)
IPO (17474)
IRA (57)
Job creations (4518)
Job search strategy (1924)
Kidney cancer (13)
Labor market (55)
Layoffs (576)
Leadership (24)
Legal (9051)
Liver cancer (84)
Longevity (12)
Lung cancer (438)
Lymphoma (224)
Machine learning (11)
Management (62)
Manufacturing (463)
MASH (102)
Medical device (14446)
Medtech (14452)
Mergers & acquisitions (21467)
Metabolic disorders (952)
Multiple sclerosis (106)
NASH (21)
Neurodegenerative disease (159)
Neuropsychiatric disorders (44)
Neuroscience (2368)
NextGen: Class of 2025 (7256)
Non-profit (4919)
Now hiring (50)
Obesity (483)
Opinion (280)
Ovarian cancer (106)
Pain (128)
Pancreatic cancer (133)
Parkinson's disease (201)
Partnered (23)
Patents (335)
Patient recruitment (185)
Peanut (54)
People (63548)
Pharmaceutical (110)
Pharmacy benefit managers (25)
Phase I (22396)
Phase II (31533)
Phase III (23609)
Pipeline (1777)
Policy (240)
Postmarket research (2946)
Preclinical (9802)
Press Release (72)
Prostate cancer (155)
Psychedelics (44)
Radiopharmaceuticals (276)
Rare diseases (530)
Real estate (6845)
Recruiting (69)
Regulatory (25125)
Reports (51)
Research institute (2607)
Resumes & cover letters (436)
Rett syndrome (10)
RNA editing (12)
RSV (60)
Schizophrenia (103)
Series A (172)
Series B (120)
Service/supplier (15)
Sickle cell disease (69)
Special edition (21)
Spinal muscular atrophy (160)
Sponsored (37)
Startups (4105)
State (2)
Stomach cancer (17)
Supply chain (85)
Tariffs (69)
The Weekly (87)
Vaccines (904)
Venture capital (60)
Weight loss (320)
Women's health (51)
Worklife (19)
Date
Today (134)
Last 7 days (561)
Last 30 days (1907)
Last 365 days (32923)
2025 (19028)
2024 (37373)
2023 (42219)
2022 (53610)
2021 (58335)
2020 (57075)
2019 (50281)
2018 (38161)
2017 (35557)
2016 (35785)
2015 (41863)
2014 (36218)
2013 (31922)
2012 (33683)
2011 (33991)
2010 (32430)
Location
Africa (997)
Alabama (72)
Alaska (7)
Arizona (264)
Arkansas (14)
Asia (46259)
Australia (7665)
California (7915)
Canada (2474)
China (735)
Colorado (340)
Connecticut (353)
Delaware (211)
Europe (102579)
Florida (1192)
Georgia (265)
Hawaii (2)
Idaho (63)
Illinois (715)
India (31)
Indiana (392)
Iowa (18)
Japan (248)
Kansas (115)
Kentucky (32)
Louisiana (17)
Maine (73)
Maryland (1116)
Massachusetts (6014)
Michigan (273)
Minnesota (488)
Mississippi (4)
Missouri (105)
Montana (31)
Nebraska (26)
Nevada (85)
New Hampshire (73)
New Jersey (2218)
New Mexico (31)
New York (2213)
North Carolina (1217)
North Dakota (10)
Northern California (3462)
Ohio (257)
Oklahoma (17)
Oregon (40)
Pennsylvania (1704)
Puerto Rico (18)
Rhode Island (38)
South America (1368)
South Carolina (36)
South Dakota (1)
Southern California (2963)
Tennessee (130)
Texas (1209)
United States (29724)
Utah (232)
Virginia (213)
Washington D.C. (77)
Washington State (687)
West Virginia (4)
Wisconsin (85)
787,318 Results for "otsuka pharmaceutical development and commercialization inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Adcomms
Otsuka, Lundbeck Fail To Sway Adcomm on Rexulti Combo for PTSD
Otsuka and Lundbeck’s data are insufficient to establish significant efficacy of Rexulti plus sertraline in PTSD, according to the FDA’s outside experts.
July 21, 2025
·
2 min read
·
Tristan Manalac
IgA nephropathy
Otsuka Sees ‘Impressive’ Proteinuria Reduction in Phase III IgAN Trial
Otsuka’s investigational antibody sibeprenlimab approximately halved levels of this key biomarker in patients with immunoglobulin A nephropathy.
June 6, 2025
·
2 min read
·
Tristan Manalac
Press Releases
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
May 1, 2025
·
7 min read
Press Releases
Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical
July 15, 2025
·
4 min read
Pharm Country
Otsuka to Terminate Development of AVP-786
Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. announce termination of development of the novel compound AVP-786, which was in development as a potential treatment for patients with agitation associated with dementia due to Alzheimer’s disease.
May 22, 2024
·
2 min read
Neuropsychiatric disorders
Otsuka, Lundbeck’s PTSD Bid for Rexulti Hits Speedbump as FDA Questions Efficacy
FDA reviewers flag “discordant results” in a briefing document published ahead of Friday’s advisory committee meeting for the partners’ application for the antipsychotic in post-traumatic stress disorder.
July 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
June 23, 2025
·
4 min read
Press Releases
Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
June 6, 2025
·
10 min read
Press Releases
Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
May 27, 2025
·
6 min read
Alzheimer’s disease
As Alzheimer’s Space Heats Up, Biopharma Leans In to Holistic Treatment
Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, Otsuka and Lundbeck are renewing a decades-old search for symptomatic treatments, including in high-profile drugs like Cobenfy.
July 28, 2025
·
7 min read
·
Heather McKenzie
1 of 78,732
Next
